ユーイング肉腫治療の世界市場予測・分析2019-2023

◆英語タイトル:Ewing's Sarcoma Treatment Market by Type and Geography - Global Forecast and Analysis 2019-2023
◆商品コード:IRTNTR32087
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年9月28日
◆ページ数:156
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、ユーイング肉腫治療の世界市場について調べ、ユーイング肉腫治療の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、ユーイング肉腫治療の市場規模をセグメンテーション別(種類別(併用療法、単独療法)、)と地域別(グローバル)に分けて算出しました。Technavio社はユーイング肉腫治療の世界市場規模が2019-2023期間中に年平均6%成長すると予測しています。
・サマリー
・レポートの範囲
・ユーイング肉腫治療の市場状況
・ユーイング肉腫治療の市場規模
・ユーイング肉腫治療の市場予測
・ユーイング肉腫治療の世界環境:ファイブフォース分析
・市場セグメンテーション:種類別(併用療法、単独療法)
・ユーイング肉腫治療の顧客状況
・主要地域別市場規模:グローバル
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Ewing’s Sarcoma Treatment Market: About this market

Technavio’s Ewing’s sarcoma treatment market analysis considers sales from monotherapy and combination therapy types. Our study also finds the sales of Ewing’s sarcoma treatment in Asia, Europe, North America, and ROW. In 2018, the combination therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high efficacy of combination therapy in treating Ewing’s sarcoma will play a significant role in the combination therapy segment to maintain its market position. Also, our global Ewing’s sarcoma treatment market report looks at factors such as the growing awareness about and funding for Ewing’s sarcoma, regulatory incentives, and financial assistance programs and reimbursement schemes. However, lack of approved therapies for Ewing’s sarcoma, absence of predictive biomarkers in Ewing’s sarcoma, and side-effects of chemotherapy may hamper the growth of the Ewing’s sarcoma treatment industry over the forecast period.

Global Ewing’s Sarcoma Treatment Market: Overview

Financial assistance programs and reimbursement schemes

The increasing cost of therapeutics for the treatment of various indications is encouraging governments of various countries and pharmaceutical vendors to introduce several financial assistance programs and reimbursement schemes. There are several drug assistance programs that offer payment limitation programs for costly medications such as chemotherapeutics. GlaxoSmithKline, Merck, and Pfizer are some of the prominent vendors providing prescription drug assistance programs to patients. Such assistance programs increase the patient adherence to drug treatment which will eventually lead to the expansion of the global Ewing’s sarcoma treatment market at a CAGR of almost 6% during the forecast period.

Emergence of regenerative therapies

Regenerative medicines, including gene therapy, are gaining traction in the market. This is encouraging several pharmaceutical companies to study and develop a gene therapy to treat metastatic Ewing’s sarcoma and recurrent Ewing’s tumors. The new therapeutic methods help in minimizing tumor cell proliferation in advance Ewing’s sarcoma. For instance, Gradalis is conducting a Phase I clinical trial to evaluate pbi-shRNA EWS/FLI1 Type 1 LPX, an anti-stathmin gene therapy.The growing focus on advancing regenerative medicines in clinical phases is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global Ewing’s sarcoma treatment market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global Ewing’s sarcoma treatment market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Ewing’s sarcoma treatment manufacturers, that include Amneal Pharmaceuticals Inc., Baxter International Inc., Bristol-Myers Squibb Co., Eli Lilly and Co., Merck & Co. Inc., Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Also, Ewing’s sarcoma treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all future growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

Combination therapy – Market size and forecast 2018-2023

Monotherapy – Market size and forecast 2018-2023

Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 10: MARKET TRENDS

Strong pipeline

Emergence of regenerative therapies

Advent of CRISPR-Cas9 technology

PART 11: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 12: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Amneal Pharmaceuticals Inc.

Baxter International Inc.

Bristol-Myers Squibb Co.

Eli Lilly and Co.

Merck & Co., Inc.

Mylan NV

Novartis AG

Pfizer Inc.

Sun Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd.

PART 13: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 14: EXPLORE TECHNAVIO

Exhibit 01: Product Overview

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Type – Market share 2018-2023 (%)

Exhibit 19: Comparison by type

Exhibit 20: Combination therapy – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Combination therapy – Year-over-year growth 2019-2023 (%)

Exhibit 22: Monotherapy – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Monotherapy – Year-over-year growth 2019-2023 (%)

Exhibit 24: Market opportunity by type

Exhibit 25: Customer landscape

Exhibit 26: Market share by geography 2018-2023 (%)

Exhibit 27: Geographic comparison

Exhibit 28: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 29: North America – Year-over-year growth 2019-2023 (%)

Exhibit 30: Top 3 countries in North America

Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 33: Top 3 countries in Europe

Exhibit 34: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 35: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 36: Top 3 countries in Asia

Exhibit 37: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 38: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 39: Top 3 countries in ROW

Exhibit 40: Key leading countries

Exhibit 41: Market opportunity

Exhibit 42: Impact of drivers and challenges

Exhibit 43: Vendor landscape

Exhibit 44: Landscape disruption

Exhibit 45: Vendors covered

Exhibit 46: Vendor classification

Exhibit 47: Market positioning of vendors

Exhibit 48: Amneal Pharmaceuticals Inc. – Vendor overview

Exhibit 49: Amneal Pharmaceuticals Inc. – Business segments

Exhibit 50: Amneal Pharmaceuticals Inc. – Organizational developments

Exhibit 51: Amneal Pharmaceuticals Inc. – Segment focus

Exhibit 52: Amneal Pharmaceuticals Inc. – Key offerings

Exhibit 53: Amneal Pharmaceuticals Inc. – Key customers

Exhibit 54: Baxter International Inc. – Vendor overview

Exhibit 55: Baxter International Inc. – Business segments

Exhibit 56: Baxter International Inc. – Organizational developments

Exhibit 57: Baxter International Inc. – Segment focus

Exhibit 58: Baxter International Inc. – Key offerings

Exhibit 59: Baxter International Inc. – Key customers

Exhibit 60: Bristol-Myers Squibb Co. – Vendor overview

Exhibit 61: Bristol-Myers Squibb Co. – Business segments

Exhibit 62: Bristol-Myers Squibb Co. – Organizational developments

Exhibit 63: Bristol-Myers Squibb Co. – Geographic focus

Exhibit 64: Bristol-Myers Squibb Co. – Key offerings

Exhibit 65: Bristol-Myers Squibb Co. – Key customers

Exhibit 66: Eli Lilly and Co. – Vendor overview

Exhibit 67: Eli Lilly and Co. – Business segments

Exhibit 68: Eli Lilly and Co. – Organizational developments

Exhibit 69: Eli Lilly and Co. – Geographic focus

Exhibit 70: Eli Lilly and Co. – Segment focus

Exhibit 71: Eli Lilly and Co. – Key offerings

Exhibit 72: Eli Lilly and Co. – Key customers

Exhibit 73: Merck & Co. Inc. – Vendor overview

Exhibit 74: Merck & Co. Inc. – Business segments

Exhibit 75: Merck & Co. Inc. – Organizational developments

Exhibit 76: Merck & Co. Inc. – Geographic focus

Exhibit 77: Merck & Co. Inc. – Segment focus

Exhibit 78: Merck & Co. Inc. – Key offerings

Exhibit 79: Merck & Co. Inc. – Key customers

Exhibit 80: Mylan NV – Vendor overview

Exhibit 81: Mylan NV – Product segments

Exhibit 82: Mylan NV – Organizational developments

Exhibit 83: Mylan NV – Geographic focus

Exhibit 84: Mylan NV – Segment focus

Exhibit 85: Mylan NV – Key offerings

Exhibit 86: Mylan NV – Key customers

Exhibit 87: Novartis AG – Vendor overview

Exhibit 88: Novartis AG – Business segments

Exhibit 89: Novartis AG – Organizational developments

Exhibit 90: Novartis AG – Geographic focus

Exhibit 91: Novartis AG – Segment focus

Exhibit 92: Novartis AG – Key offerings

Exhibit 93: Novartis AG – Key customers

Exhibit 94: Pfizer Inc. – Vendor overview

Exhibit 95: Pfizer Inc. – Business segments

Exhibit 96: Pfizer Inc. – Organizational developments

Exhibit 97: Pfizer Inc. – Geographic focus

Exhibit 98: Pfizer Inc. – Segment focus

Exhibit 99: Pfizer Inc. – Key offerings

Exhibit 100: Pfizer Inc. – Key customers

Exhibit 101: Sun Pharmaceutical Industries Ltd. – Vendor overview

Exhibit 102: Sun Pharmaceutical Industries Ltd. – Business segments

Exhibit 103: Sun Pharmaceutical Industries Ltd. – Organizational developments

Exhibit 104: Sun Pharmaceutical Industries Ltd. – Geographic focus

Exhibit 105: Sun Pharmaceutical Industries Ltd. – Key offerings

Exhibit 106: Sun Pharmaceutical Industries Ltd. – Key customers

Exhibit 107: Teva Pharmaceutical Industries Ltd. – Vendor overview

Exhibit 108: Teva Pharmaceutical Industries Ltd. – Business segments

Exhibit 109: Teva Pharmaceutical Industries Ltd. – Organizational developments

Exhibit 110: Teva Pharmaceutical Industries Ltd. – Segment focus

Exhibit 111: Teva Pharmaceutical Industries Ltd. – Key offerings

Exhibit 112: Teva Pharmaceutical Industries Ltd. – Key customers

Exhibit 113: Validation techniques employed for market sizing

Exhibit 114: Definition of market positioning of vendors



【掲載企業】

Amneal Pharmaceuticals Inc.
Baxter International Inc.
Bristol-Myers Squibb Co.
Eli Lilly and Co.
Merck & Co., Inc.
Mylan NV
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ユーイング肉腫治療の世界市場予測・分析2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆